Grand Journal of Urology
E-ISSN : 2757-7163

The Effect of Curcumin on Penile Fibrotic Plaque in Rats with Experimental Peyronie's Disease
Mahmut Ulubay1, Aysenur Kaya2, Arife Ahsen Kaplan3, Kiymet Kubra Tufekci4, Ekrem Akdeniz5, Suleyman Kaplan6
1Department of Urology, Samsun University, Faculty of Medicine, Samsun, Türkiye
2Department of Histology and Embryology, Karamanoglu Mehmetbey University, Faculty of Medicine, Karaman, Türkiye
3Department of Histology and Embryology, Istanbul Medipol University, Faculty of Medicine, Istanbul, Türkiye
4Department of Histology and Embryology, Faculty of Medicine, Kastamonu University, Kastamonu, Türkiye
5Department of Urology, Health Sciences University, Samsun Training and Research Hospital, Samsun, Türkiye
6Department of Histology and Embryology, Ondokuz Mayıs University, Faculty of Medicine, Samsun, Türkiye
DOI : 10.5505/GJU.2023.62207
Pages : 102-108


Objective: No effective medical approach for the treatment of Peyronie's disease (PD) has to date been described. This study was intended to evaluate the antifibrotic, antioxidant, and antiinflammatory effects of curcumin on fibrotic tissue in the tunica albuginea (TA) in a rat model of PD.

Materials and Methods: Twenty-four male Sprague Dawley rats aged 10 months were randomized into three groups (n = 8 in each). No PD model was induced in the control group. The PD+saline (PD+Ps) group received fibrin injection, followed two weeks later by saline administration by oral gavage for 14 days. The PD+Curcumin (PD+Cur) group received fibrin injection into the TA followed two weeks later by curcumin administration by oral gavage for 14 days. At the end of the experiment, fibrotic activity was evaluated using stereological and histopathological methods. Transforming growth factor-β1 (TGF-β1), one of the most fibrogenic cytokines, was evaluated using immunohistochemistry with an anti-TGF-β1 rabbit monoclonal antibody.

Results: Stereological analysis revealed significantly greater Peyronie-like plaque areas in the TA in the PD+Ps group than in the control and PD+Cur groups (p<0.0001). No significant difference was observed between the control and PD+Cur groups (p=0.35). The PD+Ps group exhibited strong TGF-β1 immunoreactivity with increased expression in the collagenous connective tissues and fibroblasts around the TA.

Conclusion: Curcumin reduced fibrotic tissue in the TA and may represent a novel therapeutic option in the treatment of PD.


Peyronie's disease (PD) is a condition that progresses with fibrosis in the tunica albuginea (TA) layer of the penis and therefore causes penile pain, curvature, and sexual dysfunction. Despite being frequently seen, its aetiology and pathophysiology are not yet fully understood [1,2]. Factors such as trauma, frequency of sexual intercourse, diabetes mellitus, Dupuytren's contracture, family history, gout, plantar facial contracture, radical prostatectomy, tympanosclerosis, Paget's disease, beta-blocker use, advancing age, genetic predisposition, smoking, hypertension, and tissue ischemia may play a role in the aetiology [1,3,4]. The most widely accepted theory involves abnormal collagen and glycosaminoglycan deposition in the TA after inflammation and fibroblast proliferation caused by repetitive microtraumas. Abnormal extracellular matrix production also occurs through increased myofibroblast activity and upregulation of tissue inhibitors of matrix metalloproteinases [2]. The prevalence of PD ranges from 3.2% to 8.9%, with patients being typically aged 50-60 years [5].

PD includes two phases, acute (inflammatory) and chronic (stable). The acute inflammatory phase usually lasts 6-18 months and is characterized by painful erections, the formation of a palpable nodule or plaque in the tunica of the penis and penile curvature. When the lesions stabilize, the chronic phase begins and the penile deformity stabilizes, inflammation decreases, pain improves, and erectile dysfunction symptoms develop [2]. Research has reported that the course of the disease remains stable in 47% of patients and resolves spontaneously in 13%. However, the manifestation worsens in 40% of patients, and these require active treatment [6].

Despite the many alternative treatments (antifibrotic, antiinflammatory, antioxidant drugs, various vitamins, amino acids, etc.) available in addition to surgical treatment since Francois de la Peyronie's definition of PD in 1743, no entirely satisfactory therapeutic option has still been discovered [1]. Curcumin is a yellow-orange substance obtained from the roots of the plant turmeric. It has occupied an important place in Asia for thousands of years, especially in Indian medicine, and has been the focus of scientific studies for the last 20 years. Studies have shown that curcumin possesses strong antioxidant, anti-inflammatory, antiapoptotic and antidiabetic properties. In addition to its antifibrotic property, it has also been reported to exhibit an antiproliferative effect on fibroblasts. Studies have also observed the protective effects of curcumin on pulmonary, cardiac, and renal fibrosis [7]. Considering that PD is associated with diabetes mellitus at a rate of 18-33%, the antidiabetic effect of curcumin suggests that it may be an important substance in terms of the treatment of the disease [4].

In light of this information, curcumin is worthy of note as a potential therapeutic agent capable of use in the treatment of PD. The purpose of this study was aimed to examine the efficacy of curcumin against abnormal fibrous tissue production in the TA using stereological, histopathological, and immunohistochemical methods. We think that the results obtained will be useful for the development of novel medical methods for the reduction or prevention of penile fibromatosis. This is the first experimental study in the literature to investigate the effects of curcumin in an experimental rat PD model.

Materials and Methods

The experimental protocol adopted in the current study was approved by the Ondokuz Mayıs University, Animal Care and Ethics Committee (HADYEK no. 2018-29-dated 25.05.2018). The animals were obtained from the Experimental Animals Surgical Research and Application Centre of Ondokuz Mayıs University, Samsun, Turkey. Twenty-four male Sprague Dawley rats (weighing 250-300 g, aged 10 months) were divided into three equal groups. The rats were housed instainless-steel cages under a 12-h light/12-h dark cycle at a room temperature of 22±2ºC with humidity of 50%±10 in the laboratory. Free access was allowed to food and water. The rats were cared for as specified by the guidelines related to the care and use of laboratory animals issued by the U.S. National institutes of Health (NIH Publication No. 85-23, revised 2011) [8]. This study was also conducted in conformity with the ARRIVE animal experiments guideline [9].

Peyronie's Disease Model
Physiological saline solution was injected into the TA of the rats in the control group. In the PD+saline (PD+Ps) group, 30 μL of fibrin (TISSEELVH Sealer; Baxter, Glendale, CA, USA; 30 uL each of human fibrin and thrombin solution) was injected into the TA in order to induce the formation of Peyronie-like fibrous plaques of rats, two weeks after which, saline solution was administered for 14 days by oral gavage [10]. In the PD+Curcumin (PD+Cur) group, 30 μL of fibrin was injected into the TA, two weeks after which curcumin was administered by oral gavage for 14 days [11]. Curcumin was obtained from Sigma-Aldrich Company (Sigma Aldrich, USA, Catalog number: BD9137). Curcumin was given as 30 mg/kg per day, similar to study of Huyut et al., which investigating the effects of curcumin on liver fibrosis [12]. The bioavailability of curcumin is poor due to its rapid metabolism. It has therefore been used by dissolving it in olive oil to increase oral and gastrointestinal absorption and to reduce clearance from the body in previous research [13]. At the end of the experimental procedure, all rats were anesthetized with intramuscular ketamine (50 mg/kg)/ xylazine (10 mg/kg) and subjected to transcardiac perfusion. The penile tissues were removed and examined using stereological, histopathological, and immunohistochemical methods.

Tissue Preparation
Tissue samples were subjected to routine histological tissue processing and embedded in paraffin for stereological and immunohistochemical analysis. The penile tissue of one rat from each group was embedded in resin blocks for electron microscopic analysis.

For stereological analysis, sections 5 μm in thickness were taken using the systematic random sampling method and stained with Masson's trichrome to determine histometric changes. Images were captured at 40x magnification under a microscope with a camera attachment for the analysis of plaque areas in the TA. The fibrous plaque surface areas were estimated using the planimetry method of the Cavalieri principle on Image J (Image Processing and Analysis in Java, NIH, USA) software. Coefficient of error (CE) and coefficient of variation (CV) values were calculated to determine whether the number of animals per group and sampling intervals were appropriate for each animal.

Semi-thin sections (500 nm) were taken from the resin blocks for light microscopic examination and stained with 1 % toluidine blue. Images were captured at 10x, 40x and 100x magnification for histopathological evaluation. Thin (70 nm) sections were also taken from the resin blocks for electron microscopic examination and stained with 0.5 % uranyl acetate and 3% lead citrate (Leica Ultrostain II). After staining, the sections were examined ultrastructurally under a transmission electron microscope (JEOLJSM-7001F, Japan).

For immunohistochemical evaluation, 5 μm-thick sections from each group were placed onto positively charged slides. Sections were immunestained for transforming growth factor-β1 (TGF-β1) to determine whether fibrin injection induced TGF-β1 expression and formed a Peyronie-like fibrous plaque in the TA. TGF-β1 was evaluated by immunohistochemical analysis with an anti-TGF-β1 rabbit monoclonal antibody (1:100; Abcam). Sections were cross-stained with Mayer's hematoxylin. Immunohistochemical staining was performed by the Department of Pathology at Ondokuz Mayıs University.

Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 9.0 software (GraphPad, CA, USA). All data are presented as mean ± standard error of the mean. The data were found to be normally distribution using the Shapiro-Wilk normality test. A p values less than 0.05 were considered statistically significant and all groups were analyzed using One-way ANOVA.


When all three groups had been evaluated in terms of Peyronie-like plaque areas in the TA, the plaque area in the PD+Ps group was significantly higher than those in the Control and PD+Cur groups (p<0.0001). However, no significant difference was observed between the Control and PD+Cur groups (p=0.35) (Figure 1).

Figure 1. A statistical comparison of fibrous plaque areas induced by fibrin injection in TA between three study groups. Plaque areas were expressed as mean±standard deviation. Significant differences at the level of p <0.0001 between the groups are indicated by (****)

Light microscopic images taken from semi-thin (500 nm) sections were evaluated to determine morphological changes between groups. The histological structure of the tissue was normal in the Control and PD+Cur groups, whereas abundant Peyronie-like fibrous plaques were observed in the PD+Ps group (Figure 2).

Figure 2. Light microscopic images of semi-thin sections from all groups. The TA and corpus cavernosum parts of the penile tissue are seen at small magnification (x10). The histological structure of the tissue is normal in the control group. Plaque structures were remarkable in the high magnification (x40 and x100) images of the TA in the PD+Ps group. Morphology is similar to that of the control group can be seen in the images from the PD+Cur group. Sections were stained with toluidine blue. Asterix (*); plaque.

Electron Microscopy
Thin sections of penis tissues from the animals, the Control, the PD+Ps, and the PD+Cur groups were examined by electron microscopy. The collagen fibres in TA of the Control group have a well-organised arrangement; there is no interruption of the fibres in their tunica. In the PD+Ps group, most area in the TA lost its collagen fibres, for this reason many of area in the tissue are observed as white area i.e. plaque structures. In this group, it is hard to see fasciculation of collagen fibres in the TA since pronounced collagen degeneration and formation of plaque structures. In the PD+Cur group, collagen fibres of TA are well protected after curcumin treatment except few areas in the tissue and these areas would be evaluated as plaque structures. Protective effects of curcumin in this group were observed since parallel arrangement of collagen fibers are found in the tissue (Figure 3).

Figure 3. Electron microscopic images of the penis taken from three groups that are the Cont, PD+Ps and PD+Cur groups were seen. Tunica albuginea of the Cont group has a normal structure in that collagen fibres (Col) are organised as parallel and compact in the fascicules. In the PD+Ps group, the uniformity of collagen bundles in the tunica albuginea region was seriously impaired. In most of the areas, there are no collagen fibres in the dashed line (*) or a very weak arrangement is observed. In the PD+Cur group, although some regions have a non-collagenous area (*), most places in the tunica albuginea have a well-organised collagen (Col) fibres.

Sections were immunostained for TGF-β1 expression in the TA. Positive areas for TGF-β1 were negligible in the Control and PD+Cur groups, but severe staining was observed in the PD+Ps group (Figure 4).

Figure 4. Immunohistochemical staining for TGF-β1 in all groups. In the control group, opposed arrows indicate the presence of nonsevere staining. In the PD+Ps group, severe TGF-β1 expression was observed in Peyronie-like plaques extending over a wide area in the TA. Very slight staining can be seen in the areas at the ends of the arrows in the PD+Cur group. Sections were cross-stained with Mayer's hematoxylin. Arrows; TGF-β1 expression.


PD was once considered a rare entity but is now known to be more common. Although the etiology of the disease is not fully understood, it is thought to be related to trauma resulting in abnormal wound healing [1].

Various different therapeutic modalities are recommended for PD, including both conservative (oral, topical, and intralesional treatments) and invasive (surgical) measures [1]. Surgical repair is usually performed in the form of penile plication, penile prosthesis, penile plate incision, or excision in men with significant stable penile curvature after the failure of conservative treatment approaches. Risk factors for these procedures typically include penile shortening, erectile dysfunction, and penile numbness. If the primary goal in the treatment of the disease is to correct the curvature, surgery continues to represent the gold standard [1,13]. Surgery should be avoided in the acute inflammatory phase of PD due to the risk of disease progression and recurrence of the curvature [3,14].

Conservative approaches in the treatment of PD include oral agents such as vitamin E, tamoxifen, colchicine, procarbazine, omega-3 fatty acids, potassium para-aminobenzoate (potaba), nonsteroidal anti-inflammatory drugs, L-carnitine, phosphodiesterase type 5 inhibitors, and pentoxifylline. Topical therapies include extracorporeal shockwave treatment (ESWT), topical verapamil, H-100 gel and intralesional treatments such as verapamil, nicardipine, interferon α2B, collagenase clostridium histolyticum (CCH), and hyaluronic acid and botulinum toxin. However, except for intralesional CCH, none has demonstrated a reliable and definitive clinical benefit [1].

CCH is the first Food and Drug Administration (FDA)- approved injectable drug and can be considered a reasonable alternative for patients who are unwilling to undergo surgical treatment [15]. Intralesional collagenase injection has been reported to significantly reduce plaque size and penile curvature. However, there is no evidence that it improves penile pain or erectile dysfunction. Side effects reported in the literature include ecchymosis, swelling, corporal rupture and hematoma related to the use of collagenase [16].

Stem cell and platelet-rich plasma applications are recently developed non-invasive therapeutic options, and promising results have been reported. However, despite their promising potential, their clinical efficacy has not yet been proven. Numerous randomized clinical studies investigating their longterm effects are therefore needed [17-19].

Plant-derived products have become increasingly popular in recent years as an alternative to traditional medicines. Phytochemicals isolated from plants are characterized by numerous biological activities, primarily anti-inflammatory in nature. Curcumin, also known as diferuloylmethane, is a lipophilic polyphenol derived from the roots of Curcuma longa (turmeric). It has been widely used in traditional Asian medicine for thousands of years for its anti-inflammatory and wound-healing properties [20]. Curcumin is a compound considered "generally safe" by the FDA. The source of the pharmacological effects of turmeric is mainly bioactive curcuminoids, which include curcumin, demetoxycurcumin, and bisdemethoxycurcumin [21,22].

Curcumin is known to exhibit numerous properties, such as antioxidant, anti-inflammatory, anti-diabetic, anti-apoptotic and antifibrotic activities. Recent studies suggest that curcumin modulates different molecular pathways by acting on various cytokines, transcription factors, growth factors and their associated receptors, thus playing a protective role against cardiac fibrosis [7,23,24]. Curcumin treatment has been reported to reduce inflammatory cells and improve collagen deposition in animal models [25,26]. It has also been observed to be capable of ameliorating pulmonary fibrosis, characterized by infiltration of inflammatory cells, fibrotic tissue deposition and increased collagen content [27].

The normal histological structure of the TA surrounding the penile corpora cavernosa consists of an inner circular and an outer longitudinally arranged elastin and collagen network. In the pathophysiology of PD, tissue healing is impaired leading to scarring through collagen deposition and decreased elastin, possibly due to acute or repetitive penile trauma [1,28]. In the healing process of impaired tissue, repetitive traumas to the TA cause an increase in pro-fibrotic factors such as TGF-β1 and platelet-derived growth factor and a decrease in anti-fibrotic factors [29]. TGF-β1 plays a role in soft tissue fibrosis and erectile dysfunction. It is synthesized as an inactive peptide by various cell types including platelets, macrophages, and fibroblasts. When activated, it binds to specific cell surface receptors, resulting in increased connective tissue synthesis and inhibition of collagenases [29,30].

Stereological analyses in the present study revealed that the numerical data for fibrous plaque areas in the control and PD+Cur groups were close to one another, although there was a significant difference between them and the PD+Ps group. Electron microscopic evaluation of the tissues taken from the groups supported the stereological analysis, since few number of plaque structures in the PD+Cur group in comparison of the PD+Ps group. Immunohistochemical analyses revealed intense TGF-β1 expression in the PD+Ps group. In contrast, a small amount of positive staining was observed in the TA in the PD+Cur group. In light of all these data, it may be concluded that curcumin may play a potential role in the treatment of PD by exhibiting anti-fibrotic activity.


Pharmacotherapeutic approaches are not yet effective or widely accepted in the treatment of PD. Surgical removal of plaque or the installation of penile prostheses continues to be considered the mainstay of treatment. Curcumin, a plant-derived compound, reverses the effect of pro-fibrotic factors by affecting the expression and activation of various intracellular molecules. Curcumin treatment in this study reduced TA fibrosis in an experimentally induced rat PD model. Our results suggest that curcumin may represent a new oral therapeutic option in the treatment of PD. Although our findings are promising and suggest a possible oral medical treatment for PD, further studies are needed on the subject.

Acknowledgements: We would like to thank to our lab technician who is Huseyin Saricaoglu for his helps during tissue processing. We also thank native English speaker Carl Nino Rossini for his excellent language revision.

Ethics Committee Approval: The experimental protocol adopted in the current study was approved by the Ondokuz Mayıs University, Animal Care and Ethics Committee (HADYEK no. 2018-29-dated 25.05.2018).

Informed Consent: An informed consent was obtained from all the patients.

Publication: The results of the study were not published in full or in part in form of abstracts.

Peer-review: Externally and internally peer-reviewed. Authorship Contributions: Any contribution was not made by any individual not listed as an author. Concept – M.U., A.K.; Design – M.U., A.K.; Supervision – M.U., A.K.; Resources – A.A.K., K.K.T., E.A.; Materials – A.A.K., K.K.T., E.A.; Data Collection and/or Processing – A.A.K., K.K.T., E.A.; Analysis and/or Interpretation – M.U., A.K.; Literature Search – A.A.K., K.K.T., E.A.; Writing Manuscript – M.U., A.K.; Critical Review – M.U., S.K.

Conflict of Interest: The authors declare that they have no conflicts of interest.

Financial Disclosure: The authors declare that this study received no financial support.


1) Salonia A, Bettocchi C, Carvalho J, Corona G, Jones TH, Kadioglu A, et al. European Association of Urology Guidelines on Sexual and Reproductive Health. 8. Access: 1 July 2023

2) Ziegelmann MJ, Bajic P, Levine LA. Peyronie's disease: Contemporary evaluation and management. Int J Urol 2020;27:504-16.

3) Bilgutay AN, Pastuszak AW. Peyronie's disease: a review of etiology, diagnosıs, and management. Curr Sex Health Rep 2015;7:117-31.

4) Kendirci M, Trost L, Sikka SC, Hellstrom WJ. Diabetes mellitus is associated with severe Peyronie's disease. BJU Int 2007;99:383-6.

5) Capoccia E, Levine LA. Contemporary Review of Peyronie's Disease Treatment. Curr Urol Rep 2018;19:51.

6) Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990;144:1376-9.

7) Slika L, Patra D. Traditional Uses, Therapeutic Effects and Recent Advances of Curcumin: A Mini-Review. Mini Rev Med Chem 2020;20:1072-82.

8) Guide for the care and use of laboratory animals. Washington (DC): National Academies Press, USA, 2011.

9) McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 2010;160:1573-6.

10) Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease. BJU Int 2003;91:830-8.

11) Sharma S, Kulkarni SK, Agrewala JN, Chopra K. Curcumin attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain. Eur J Pharmacol 2006;53:256-61.

12) Huyut Z, Uçar B, Altındağ F, Yıldızhan K, Huyut MT. Effect of curcumin on lipid profile, fibrosis, and apoptosis in liver tissue in abemaciclib-administered rats. Drug Chem Toxicol 2022;19:1-9.

13) Stohs SJ, Chen O, Ray SD, Ji J, Bucci LR, Preuss HG. Highly Bioavailable Forms of Curcumin and Promising Avenues for Curcumin-Based Research and Application: A Review. Molecules 2020;25:1397.

14) Carson C. Peyronie's disease: new paradigm for the treatment of a unique cause of erectile dysfunction. Postgrad Med 2020;132:4-8.

15) Abdel Raheem A, Johnson M, Ralph D, Garaffa G. Collagenase clostridium histolyticum: a novel medical treatment for Peyronie's disease. Minerva Urol Nefrol 2018;70:380-5.

16) Yang KK, Bennett N. Peyronie's Disease and Injectable Collagenase Clostridium histolyticum: Safety, Efficacy, and Improvements in Subjective Symptoms. Urology 2016;94:143-7.

17) Goldstein I, Hartzell R, Shabsigh R. The Impact of Peyronie's Disease on the Patient: Gaps in Our Current Understanding. J Sex Marital Ther 2016;42(2):178-90.

18) Moussa M, Abou Chakra M, Moussa Y. Advances in stem cell therapy for the treatment of Peyronie's disease. Intractable Rare Dis Res 2020;9:10-13.

19) Merecz-Sadowska A, Sitarek P, Śliwiński T, Zajdel R. Anti- Inflammatory Activity of Extracts and Pure Compounds Derived from Plants via Modulation of Signaling Pathways, Especially PI3K/AKT in Macrophages. Int J Mol Sci 2020;21:9605.

20) Jennings MR, Parks RJ. Curcumin as an Antiviral Agent. Viruses 2020;12:1242.

21) Filardi T, Varì R, Ferretti E, Zicari A, Morano S, Santangelo C. Curcumin: Could This Compound Be Useful in Pregnancy and Pregnancy-Related Complications? Nutrients 2020;12:3179.

22) Kotha RR, Luthria DL. Curcumin: Biological, Pharmaceutical, Nutraceutical, and Analytical Aspects. Molecules 2019;24:2930.

23) Fang G, Chen S, Huang Q, Chen L, Liao D. Curcumin suppresses cardiac fibroblasts activities by regulating the proliferation and cell cycle via the inhibition of the p38 MAPK/ERK signaling pathway. Mol Med Rep 2018;18:1433-8.

24) Gorabi AM, Hajighasemi S, Kiaie N, Rosano GMC, Sathyapalan T, Al-Rasadi K, et al. Anti-fibrotic effects of curcumin and some of its analogues in the heart. Heart Fail Rev 2020;25:731-43.

25) Avasarala S, Zhang F, Liu G, Wang R, London SD, London L. Curcumin modulates the inflammatory response and inhibits subsequent fibrosis in a mouse model of viralinduced acute respiratory distress syndrome. PLoS One 2013;8:e57285.

26) Johnson S, Shaikh SB, Muneesa F, Rashmi B, Bhandary YP. Radiation induced apoptosis and pulmonary fibrosis: curcumin an effective intervention? Int J Radiat Biol 2020;96:709-17.

27) Lee JC, Kinniry PA, Arguiri E, Serota M, Kanterakis S, Chatterjee S, et al. Dietary curcumin increases antioxidant defenses in lung, ameliorates radiation-induced pulmonary fibrosis, and improves survival in mice. Radiat Res 2010;173:590-601.

28) Li EV, Esterquest R, Pham MN, Panken EJ, Amarasekera C, Siebert A, et al. Peyronie's disease: pharmacological treatments and limitations. Expert Rev Clin Pharmacol 2021;14:703-13.

29) Border WA, Ruoslahti E. Transforming growth factorbeta in disease: the dark side of tissue repair. J Clin Invest 1992;90:1-7.

30) Moreland RB, Nehra A. Pathophysiology of Peyronie's disease. Int J Impot Res 2002;14:406-10.

Keywords : Peyronie's disease, curcumin, fibrin, antioxidant

Viewed : 1739
Downloaded : 348